-

Shareholder Alert: Robbins LLP Reminds Investors the Lead Plaintiff Deadline is Approaching for Canopy Growth Corp. (CGC)

SAN DIEGO & SMITHS FALLS, Ontario--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Canopy Growth Corp. (NYSE: CGC) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between June 21, 2019 and November 13, 2019. Canopy produces, distributes, and sells cannabis in Canada.

If you suffered a loss as a result of Canopy's misconduct, click here.

Canopy Growth Corp.'s (CGC) Accused of Misleading Shareholders

According to the complaint, in June 2019, Canopy filed its Form 6-K with the SEC, touting fourth quarter 2019 sales of CA$42.5 million and fiscal year 2019 sales of CA$85.3 million from its cannabis oils and softgel capsules, noting that "[o]il and softgel capsules accounted for 40% of gross revenue in the fourth quarter of fiscal '19." Then, in August 2019, Canopy released first quarter 2020 cannabis oil and softgel sales of only CA$0.2 million. However Canopy's CEO assured investors that its "oils and softgel products remain exceptionally popular." Despite these assurances, in reality, Canopy was experiencing weak demand for its softgel and oil products. As a result, on November 14, 2019, Canopy issued a press release announcing an "astounding" larger-than-expected loss for the quarter, and a CA$32.7 million restructuring charge to modify its retail pricing architecture. On this news, Canopy's share price fell $2.36, or nearly 14.4%, to close at $15.84 per share.

If you purchased Canopy Growth Corp. (CGC) securities between June 21, 2019 and November 13, 2019, you have until January 21, 2020, to ask the court to be appointed lead plaintiff for the class.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:CGC

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom